Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 3
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with…
Heart Failure With Preserved Ejection Fraction (HFpEF)Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Estimated
~$10 – $7,500
AstraZenecaNCT07761117
Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitali…
Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesity
Estimated
~$10 – $7,500
AmgenNCT07037459